Hemophilia Drugs Market Size Share Growth Trends Future Forecast to 2032

Global Hemophilia Drugs Market Analysis

The global hemophilia drugs market is projected to grow from $15.40 billion in 2025 to $21.46 billion by 2032, with a compound annual growth rate (CAGR) of 4.9%.

Market Leadership

North America dominates the market with a 36.63% share in 2024, driven by pharmaceutical company strategies and high prevalence of hemophilia A & B in the U.S. and Canada.

Key Market Segments

By Disease Type

• Hemophilia A: Holds 85% market share
• Hemophilia B
• Hemophilia C

By Therapy Type

• Recombinant therapy
• Plasma-derived
• Others (gene therapy, biospecific drugs)

Distribution Channels

• Hospital pharmacy
• Retail pharmacy
• Online pharmacy

Market Drivers

• FDA approval of new treatments like Bayer's Jivi for Hemophilia A patients aged 12 and above
• Approximately 400 babies born with hemophilia A annually in the U.S.
• Increased R&D investment from pharmaceutical companies
• Growing awareness and government initiatives for rare diseases

Leading Companies

Three companies control over 50% of market revenue:

• Takeda Pharmaceutical Company Limited
• F. Hoffmann-La Roche Ltd
• Novo Nordisk

Recent Developments

• July 2021: BioMarin received EMA approval for valoctocogene roxaparvovec gene therapy
• May 2021: CSL Behring completed agreement with uniQure for etranacogene dezaparvovec
• July 2020: Spark Therapeutics published Phase I/II trial data for SPK-8011

Report-

Fortune Business Insights - Hemophilia Drugs Market Size, Share & Growth Forecast, 2032

https://www.fortunebusinessinsights.com/industry-reports/hemophilia-drugs-market-100068